Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 19

1.

Improved tumor immunity using anti-tyrosinase related protein-1 monoclonal antibody combined with DNA vaccines in murine melanoma.

Saenger YM, Li Y, Chiou KC, Chan B, Rizzuto G, Terzulli SL, Merghoub T, Houghton AN, Wolchok JD.

Cancer Res. 2008 Dec 1;68(23):9884-91. doi: 10.1158/0008-5472.CAN-08-2233.

2.

CTLA-4 blockade increases antigen-specific CD8(+) T cells in prevaccinated patients with melanoma: three cases.

Yuan J, Ginsberg B, Page D, Li Y, Rasalan T, Gallardo HF, Xu Y, Adams S, Bhardwaj N, Busam K, Old LJ, Allison JP, Jungbluth A, Wolchok JD.

Cancer Immunol Immunother. 2011 Aug;60(8):1137-46. doi: 10.1007/s00262-011-1011-9. Epub 2011 Apr 5. Review.

3.

Review: dendritic cell immunotherapy for melanoma.

Hadzantonis M, O'Neill H.

Cancer Biother Radiopharm. 1999 Feb;14(1):11-22. Review.

PMID:
10850282
4.

The future of interleukin-2: enhancing therapeutic anticancer vaccines.

Overwijk WW, Theoret MR, Restifo NP.

Cancer J Sci Am. 2000 Feb;6 Suppl 1:S76-80. Review.

5.

A comparison and critical analysis of preclinical anticancer vaccination strategies.

Kochenderfer JN, Gress RE.

Exp Biol Med (Maywood). 2007 Oct;232(9):1130-41. Review.

PMID:
17895521
6.

Cancer vaccines: Trafficking of tumor-specific T cells to tumor after therapeutic vaccination.

Hailemichael Y, Overwijk WW.

Int J Biochem Cell Biol. 2014 Aug;53:46-50. doi: 10.1016/j.biocel.2014.04.019. Epub 2014 May 2. Review.

7.

Antigen presenting cell/ tumor cell fusion vaccines for cancer immunotherapy.

Browning MJ.

Hum Vaccin Immunother. 2013 Jul;9(7):1545-8. doi: 10.4161/hv.24235. Epub 2013 Mar 8. Review.

8.

[Immunotherapy for colorectal cancer].

Tougeron D, Fauquembergue É, Latouche JB.

Bull Cancer. 2013 Sep;100(9):871-85. doi: 10.1684/bdc.2013.1800. Review. French.

PMID:
23917703
9.

Immunotherapy for advanced melanoma.

Fang L, Lonsdorf AS, Hwang ST.

J Invest Dermatol. 2008 Nov;128(11):2596-605. doi: 10.1038/jid.2008.101. Review.

10.

Xenogene vaccination in the therapy of cancer.

Cavallo F, Aurisicchio L, Mancini R, Ciliberto G.

Expert Opin Biol Ther. 2014 Oct;14(10):1427-42. doi: 10.1517/14712598.2014.927433. Epub 2014 Jul 15. Review.

PMID:
25023219
11.

Peptide intra-tumor injection for cancer immunotherapy: enhancement of tumor cell antigenicity is a novel and attractive strategy.

Nobuoka D, Yoshikawa T, Fujiwara T, Nakatsura T.

Hum Vaccin Immunother. 2013 Jun;9(6):1234-6. doi: 10.4161/hv.23990. Epub 2013 Feb 14. Review.

12.

Immunotherapy in gastric cancer.

Matsueda S, Graham DY.

World J Gastroenterol. 2014 Feb 21;20(7):1657-66. doi: 10.3748/wjg.v20.i7.1657. Review.

13.

Targeting CD8+ T-cell tolerance for cancer immunotherapy.

Jackson SR, Yuan J, Teague RM.

Immunotherapy. 2014;6(7):833-52. doi: 10.2217/imt.14.51. Review.

14.
15.

CD73: a novel target for cancer immunotherapy.

Zhang B.

Cancer Res. 2010 Aug 15;70(16):6407-11. doi: 10.1158/0008-5472.CAN-10-1544. Epub 2010 Aug 3. Review.

16.

Blocking monoclonal antibodies of TIM proteins as orchestrators of anti-tumor immune response.

Baghdadi M, Takeuchi S, Wada H, Seino K.

MAbs. 2014;6(5):1124-32. doi: 10.4161/mabs.32107. Epub 2014 Oct 30. Review.

17.

Electro-gene-transfer as a new tool for cancer immunotherapy in animals.

Impellizeri JA, Ciliberto G, Aurisicchio L.

Vet Comp Oncol. 2014 Dec;12(4):310-8. doi: 10.1111/vco.12006. Epub 2012 Oct 25. Review.

PMID:
23095099
18.

Why has active immunotherapy not worked in lung cancer?

Thomas A, Giaccone G.

Ann Oncol. 2015 Nov;26(11):2213-20. doi: 10.1093/annonc/mdv323. Epub 2015 Jul 30. Review.

PMID:
26232492
19.

Cancer immunology and canine malignant melanoma: A comparative review.

Atherton MJ, Morris JS, McDermott MR, Lichty BD.

Vet Immunol Immunopathol. 2016 Jan;169:15-26. doi: 10.1016/j.vetimm.2015.11.003. Epub 2015 Dec 1. Review.

PMID:
26827834
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk